Evidence map›Paper›PMID 37237865›Full record

ArticleAntioxidants (Basel, Switzerland)2023

Xiaoyu Wu, Jiajia Wei, Yang Yi, Guotao Shu, Zhixu He, Qihai Gong, Jianmei Gao

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. A comprehensive narrative review ofJournal of pharmaceutical analysis · 2026
    Review
  4. Article
  5. Review
  6. [Icariside Ⅱ Inhibits Hepatitis B Virus and Modulates Mitochondrial FissionSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaoyu WuKey Laboratory of Basic Pharmacology, Ministry of Education and Joint International Research Laboratory of Ethnomedicine, Zunyi Medical University, Zunyi 563000, China.ORCID 0000-0003-2973-772X
Jiajia WeiKey Laboratory of Basic Pharmacology, Ministry of Education and Joint International Research Laboratory of Ethnomedicine, Zunyi Medical University, Zunyi 563000, China.
Yang YiKey Laboratory of Basic Pharmacology, Ministry of Education and Joint International Research Laboratory of Ethnomedicine, Zunyi Medical University, Zunyi 563000, China.
Guotao ShuKey Laboratory of Basic Pharmacology, Ministry of Education and Joint International Research Laboratory of Ethnomedicine, Zunyi Medical University, Zunyi 563000, China.
Zhixu HeThe Collaborative Innovation Center of Tissue Damage Repair and Regeneration, Medicine of Zunyi Medical University, Zunyi 563000, China.
Qihai GongKey Laboratory of Basic Pharmacology, Ministry of Education and Joint International Research Laboratory of Ethnomedicine, Zunyi Medical University, Zunyi 563000, China.ORCID 0000-0002-8967-337X
Jianmei GaoKey Laboratory of Basic Pharmacology, Ministry of Education and Joint International Research Laboratory of Ethnomedicine, Zunyi Medical University, Zunyi 563000, China.
Zunyi Medical University · CN

Funding

Collaborative Innovation Center of Chinese Ministry of Education No. 2020-39Guizhou Province Science and Technology Project No. Qian Ke He[2019]5406Guizhou Province Science and Technology Project No. Qian Ke He[2020]4Y192National Natural Science Foundation of China No. 32270848Natural Science Foundation of China No.82260781Science and technology planning project of Zunyi No. Qian Ke He[2021]187Science and technology planning project of Zunyi No. Qian Ke He[2021]190
6 · The paper itself

Abstract

Cerebral ischemia/reperfusion causes exacerbated neuronal damage involving excessive neuroinflammation and oxidative stress. ROS is considered a signal molecule to activate NLRP3; thus, the ROS/NLRP3/pyroptosis axis plays a vital role in the pathogenesis of cerebral ischemia/reperfusion injury (CIRI). Therefore, targeting the inhibition of the ROS/NLRP3/pyroptosis axis may be a promising therapeutic tactic for CIRI.

Indexed as

cerebral ischemic/reperfusion injuryEpimediumneuroinflammationneuron lossNLRP3

Identifiers

PMID37237865
PMCPMC10215306
OpenAlexW4367055095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.